Insights and Resources

Image interpretation training

Access Blue Earth Diagnostics PET imaging interpretation training online, any time.

Access Information and Support

Blue Earth Diagnostics understands the reimbursement process and is here to provide the support you need to help patients access our products. We can provide you and your staff with answers to common reimbursement questions, as well as the resources you need.

Blue Earth Diagnostics can connect you with a Field Reimbursement Manager to review information about local and national payer coverage requirements and to answer other reimbursement-related questions about our approved product. 

Reimbursement support helpline assists with access questions for individual patients*

Call 1-855-495-9200, Monday through Friday from 9 am to 8 pm Eastern time, for support throughout the benefit approval process.



Patient enrollment

Practice submits patient enrollment form to helpline and is contacted within 24 hours.


Benefit investigation

Helpline conducts benefit investigation and notifies practice within 24 to 48 hours.


Prior authorization assistance

Helpline assists practice in understanding PA requirements and follows up within 48 to 72 hours.


Appeal assistance

Helpline assists practice in understanding appeal requirements for a denied PA or claim.


*Helpline provides information about PA/appeals requirements and assists with submissions for sites of care.

This document contains factual information and is not intended to be legal or coding advice. Blue Earth Diagnostics does not guarantee coverage or reimbursement for our products. The information provided in this document is based upon current, general coding practices. The existence of billing codes does not guarantee coverage and payment. Payer policies vary and may change without notice. It is the providers’ responsibility to determine and submit accurate information on claims. This includes submitting such as proper codes, modifiers, charges, and invoices for the services that were rendered. The coding on claims should reflect medical necessity and be consistent with the documentation in the patient’s medical record.


18F-rhPSMA 7.3, a Unique Investigational Prostate Specific Membrane Antigen (PSMA)-Targeted PET Imaging Agent for Men with Prostate Cancer

The role of PET in post-prostatectomy radiotherapy

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Emerging role of fluciclovine in prostate cancer management